FR2768342A1 - Anti-hemorrhoidal cream for topical application - Google Patents
Anti-hemorrhoidal cream for topical application Download PDFInfo
- Publication number
- FR2768342A1 FR2768342A1 FR9711355A FR9711355A FR2768342A1 FR 2768342 A1 FR2768342 A1 FR 2768342A1 FR 9711355 A FR9711355 A FR 9711355A FR 9711355 A FR9711355 A FR 9711355A FR 2768342 A1 FR2768342 A1 FR 2768342A1
- Authority
- FR
- France
- Prior art keywords
- glycerin
- power
- astringent
- acid
- sodium citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
La présente invention concerne une crème curative aux propriétés scléro-rétractiles et fibrosantes pour application locale sur les hémorroïdes.The present invention relates to a curative cream with sclero-retractile and fibrosing properties for local application on hemorrhoids.
Jus qu'à ce jour les crèmes et traitements locaux antihémorroïdaires sont destinés, soit à calmer les crises de fluxion (traitements d'urgence, paliatifs), soit à améliorer divers facteurs de la circulation sanguine (traitements de fond, fonctionnels), mais n'ont jamais apporté une solution curative au sens anatomo-pathologique du terme, à la maladie hémorroïdaire. Until now, local anti-hemorrhoidal creams and treatments are intended either to calm seizures (emergency, palliative treatments) or to improve various factors of blood circulation (basic, functional treatments), but n have never provided a curative solution in the anatomo-pathological sense of the term, to hemorrhoidal disease.
Cette crème a pour effets, non seulement le traitement d'urgence des crises de fluxion, mais en traitement de fond la cure, c'est à dire la guérison à long terme des hémorroïdes. This cream has the effects, not only of the emergency treatment of seizures, but as a basic treatment, that is to say, the long-term healing of hemorrhoids.
Elle est constituée de quatre principes actifs qui jouent le rôle d'agents astringeants et fibrosants et dont l'association permet l'efficaåté par interpotentialisation des effets. Ces principes actifs comportent: - l'acide tanique qui est du tanin à l'ether ou acide gallotannique, extrait de la noix de Galle (glucoside complexe) au fort pouvoir astringeant - l'alun de potassium qui est un sel de potasse en poudre soluble dans le glycérol au pouvoir astringeant et caustique selon le dosage. It is made up of four active ingredients which play the role of astringent and fibrosing agents and whose association allows the effectiveness by interpotentialisation of the effects. These active ingredients include: - tannic acid which is ether tannin or gallotannic acid, extracted from gall nut (complex glucoside) with strong astringent power - potassium alum which is a powdered potassium salt soluble in glycerol with astringent and caustic power depending on the dosage.
- le citrate de sodium qui est du citrate trisodique hydraté (acide citrique saturé au bicarbonate de sodium) au pouvoir astringeant et antiseptique.- sodium citrate which is hydrated trisodium citrate (citric acid saturated with sodium bicarbonate) with astringent and antiseptic power.
- la glycérine ou glycérol à 3% d'eau qui est un trialcool, au pouvoir irritant muqueux. En dehors des principes actifs (acide tanique, alun de potassium, citrate de sodium, glycérine) la formule comprend une petite dose d'anesthésique local (chlorhydrate de procaïne) un durcisseur (aerosil) et un excipient en émulsion (cétaline). Elle est composée par la formule suivante à considérer comme une formule "moyenne". Les dosages de chaque élément sont donnés en poids correspondant à la présentation du produit en tube de 20 gr., ainsi qu'en pourcentage pour en faciliter la lecture.- glycerin or glycerol at 3% water which is a tri-alcohol, with mucosal irritant power. Apart from the active ingredients (tanic acid, potassium alum, sodium citrate, glycerin) the formula includes a small dose of local anesthetic (procaine hydrochloride) a hardener (aerosil) and an emulsion excipient (ketaline). It is composed by the following formula to be considered as an "average" formula. The dosages of each element are given in weight corresponding to the presentation of the product in a 20 gr tube, as well as in percentage to facilitate reading.
Formule dosages "moyenne" - Acide tanique 4.gr . ..... soit 20%
(tanin à I'ether ou extrait du gallnut) - Alun de potassium 0,30gr ..... ..... soit 1,5% - citrate de sodium 0,30gr .......... soit 1,5% - glycérine 0,20gr ........ soit 1% - chlorhydrate de procaine 0,20gr . soit 1% - aerosil (poudre de silice) 0,20gr .. .. soit 1% -cétaline excipient Q.S.P. 20gr. . soit 74% (émulsion de cétazal)
Il est possible de s'écarter en dosages supérieurs ou inférieurs de cette formule moyenne dans une fourchette de 0,10% à 50si de la formule totale pour chaque élément.Dosage formula "medium" - Tannic acid 4.gr. ..... or 20%
(ether tannin or gallnut extract) - Potassium alum 0.30gr ..... ..... or 1.5% - sodium citrate 0.30gr .......... either 1.5% - glycerin 0.20gr ........ or 1% - procaine hydrochloride 0.20gr. either 1% - aerosil (silica powder) 0.20gr .. .. or 1% - ketaline excipient QSP 20gr. . or 74% (cetazal emulsion)
It is possible to deviate in higher or lower dosages from this average formula in a range of 0.10% to 50si of the total formula for each element.
Le produit est présenté sous forme de "crème" de type émulsion en tube de 20 gr. sur lequel on peut remplacer le bouchon par une canule applicatrice mousse destinée à l'injection dans le canal anal. The product is presented in the form of an "emulsion" type cream in a 20 gr tube. on which the plug can be replaced by a foam applicator cannula intended for injection into the anal canal.
Le produit agit par scléro-rétraction à la fois vasculaire et muqueuse, permettant d'obtenir à terme, une fibrose cicatricielle souple. L'effet obtenu est une rétraction des paquets hémorroidaires veineux ainsi que des anastomoses artério-veineuses après une phase d e vasoconstriction entretenue par application fréquente et régulière de la crème. L'effet inflammatoire est relativement faible voire négligeable au moment de chaque application car l'action bactériostatique est importante. L'action sur le muscle lisse (sphincter) est nulle et il n'y a donc pas d'effet sphinctérien indésirable. L'action, y compris à long terme du médicament, est donc curative en ce qui concerne la pathologie hémorroïdaire (hémorroïdes anatomopathologiques et fluxions).The product acts by both vascular and mucosal sclerotherapy, making it possible to obtain flexible scar fibrosis over time. The effect obtained is a retraction of the venous hemorrhoidal packets as well as arteriovenous anastomoses after a phase of vasoconstriction maintained by frequent and regular application of the cream. The inflammatory effect is relatively weak or even negligible at the time of each application because the bacteriostatic action is important. The action on the smooth muscle (sphincter) is zero and there is therefore no undesirable sphincter effect. The action, including long-term of the drug, is therefore curative with regard to hemorrhoidal pathology (anatomopathological hemorrhoids and fluxions).
Les applications sont à pratiquer 2 à 3 fois par jour en phase de fluxion, puis une application matin et soir pendant 3 semaines, puis pour atteindre l'effet curatif une fois par jour pendant 3 mois. Le produit devra être appliqué après avoir lavé l'anus à l'eau pure et ne doit pas être appliqué avant d'aller à la selle. The applications are to be carried out 2 to 3 times a day in the phase of flux, then an application morning and evening for 3 weeks, then to reach the curative effect once a day for 3 months. The product should be applied after washing the anus with pure water and should not be applied before having a bowel movement.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9711355A FR2768342B3 (en) | 1997-09-12 | 1997-09-12 | CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9711355A FR2768342B3 (en) | 1997-09-12 | 1997-09-12 | CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2768342A1 true FR2768342A1 (en) | 1999-03-19 |
FR2768342B3 FR2768342B3 (en) | 1999-12-03 |
Family
ID=9511012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9711355A Expired - Lifetime FR2768342B3 (en) | 1997-09-12 | 1997-09-12 | CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2768342B3 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014194966A1 (en) * | 2013-06-07 | 2014-12-11 | Shrivastava Rémi | Composition for topical application comprising glycerol and tannins |
WO2021137743A1 (en) * | 2020-01-01 | 2021-07-08 | Saudi Pharmaceutical Industries & Medical Appliances Corporation Spimaco Addwaeih | Unique herbal combination for the treatment of anal fissures and wounds in pharmaceutical dosage form |
-
1997
- 1997-09-12 FR FR9711355A patent/FR2768342B3/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014194966A1 (en) * | 2013-06-07 | 2014-12-11 | Shrivastava Rémi | Composition for topical application comprising glycerol and tannins |
CN105377300A (en) * | 2013-06-07 | 2016-03-02 | 雷米·什里瓦斯塔瓦 | Composition for topical application comprising glycerol and tannins |
US9597298B2 (en) | 2013-06-07 | 2017-03-21 | Remi Shrivastava | Composition for topical application comprising glycerol and tannins |
US10335364B2 (en) | 2013-06-07 | 2019-07-02 | Remi Shrivastava | Composition for topical application comprising glycerol and tannins |
WO2021137743A1 (en) * | 2020-01-01 | 2021-07-08 | Saudi Pharmaceutical Industries & Medical Appliances Corporation Spimaco Addwaeih | Unique herbal combination for the treatment of anal fissures and wounds in pharmaceutical dosage form |
Also Published As
Publication number | Publication date |
---|---|
FR2768342B3 (en) | 1999-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4745608B2 (en) | Skin treatment using phosphoric acid derivatives of electron transfer agents | |
ES2420516T3 (en) | Topical compositions and use thereof for the treatment of conditions related to the epithelium | |
IT8024370A1 (en) | THERAPEUTIC COMPOSITION OF DIMETHYL SULPHOXIDE AND PROCEDURES FOR ITS USE | |
RU2004122429A (en) | GEL CONTAINING AT LEAST ONE RETINOID AND BENZOIL PEROXIDE | |
JPH06503567A (en) | Treatment of local infections | |
CA2764577C (en) | Method of preventing renal disease and treating symptoms thereof | |
FR2788695A1 (en) | Cosmetic composition for use as a shower gel, bathing product, foaming gel for the face comprises menthol and menthyl lactate | |
JP5765744B2 (en) | Preventive or therapeutic agent for atopic dermatitis, and external preparation | |
FR3061434A1 (en) | COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA | |
FR2694194A1 (en) | Hydrating gel, medicament and cosmetic composition containing it, process for the preparation of said gel. | |
RU2564944C1 (en) | Ointment with metronidazole, bee moth larvae extract and anaesthesine for integrated treatment of inflammatory periodontal diseases | |
FR2768342A1 (en) | Anti-hemorrhoidal cream for topical application | |
FR2646603A1 (en) | CLEANING COMPOSITION | |
JP2023038290A (en) | Leucine derivatives, compositions comprising the same, and applications thereof | |
EP1194136A1 (en) | Non-solid composition for local application | |
FR2463617A1 (en) | NOVEL SLIMMING COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES AND ESCINE | |
EP0519777A1 (en) | Galenical forms based on fresh or dried plants | |
JPH04334321A (en) | Preventive for dermatic inflammation | |
RU2467738C1 (en) | Dental ointment with chlorhexidine and aminocapronic acid for integrated treatment of inflammatory periodontal diseases | |
FR2504009A1 (en) | Topical compsns. contg. arnica extract - together with camphor, menthol and surfactant for topical treatment of inflammations and infections | |
JP2757188B2 (en) | Anti-itch agent | |
KR20210057691A (en) | A composition for prevention, improvement or treatment of skin diseases containing a Ophiopogonin-D | |
US20210030698A1 (en) | Gel containing zerumbone from bitter ginger (zingiber zerumbet) for curative treatment of diabetic ulcers | |
EP1628672A2 (en) | Composition and use of pure iodine dissolved in essential oil of melaleuca alternifolia and/or melaleuca quinquenervia | |
JP2002212048A (en) | Skin bleaching cosmetic containing natural black component extracted from muscovado |